ArticleThe Journal of clinical endocrinology and metabolism2021
Angiotensin-Converting Enzyme Inhibitors Reduce Uterine Fibroid Incidence in Hypertensive Women.
Article in The Journal of clinical endocrinology and metabolism, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- Genetic liability to multiple factors and uterine leiomyoma risk: a Mendelian randomization study.Frontiers in endocrinology · 2023Pooled it
- Improved Cardiometabolic Health with Uterine-Preserving Fibroid Treatment Compared to Hysterectomy.Journal of clinical medicine · 2026Article
- Angiotensin II drives proliferation and extracellular matrix deposition in human uterine fibroid cells in vitro.F&S science · 2026Article
- Article
- Article
- Uterine fibroids show evidence of shared genetic architecture with blood pressure traits.Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing · 2025Article
- Hypertension, Cardiovascular Risk Factors, and Uterine Fibroid Diagnosis in Midlife.JAMA network open · 2024Article
- Uterine leiomyoma causes an increase in systolic blood pressure: a two-sample Mendelian randomization study.Frontiers in endocrinology · 2024Article
- Relationship Among Surgical Fibroid Removal, Blood Pressure, and Biomarkers of Renin-Angiotensin-Aldosterone System Activation.Reproductive sciences (Thousand Oaks, Calif.) · 2023Article
- Article
- The relationship between muscle sympathetic nerve activity and systemic hemodynamics is altered in women with uterine fibroids.Physiological reports · 2022Article
- Uterine Fibroids: Hiding in Plain Sight.Physiology (Bethesda, Md.) · 2022Review
- Exploring the role of uterine fibroids in promotion of cardiovascular diseases by diabetes exposure: Findings from national health and nutrition examination survey 1999-2006.Frontiers in cardiovascular medicine · 2022Article
- Small molecule angiotensin converting enzyme inhibitors: A medicinal chemistry perspective.Frontiers in pharmacology · 2022Review
- Vascular biology of uterine fibroids: connecting fibroids and vascular disorders.Reproduction (Cambridge, England) · 2021Review
- Role of inflammation in benign gynecologic disorders: from pathogenesis to novel therapies†.Biology of reproduction · 2021Review
- Fast Forward: Fibroid Management in 2042.F&S science · 2021Article
Corrections and comments
- Commented on by
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
contextIn vitro and in vivo evidence has supported the role of angiotensin II blockade in reducing leiomyoma cell proliferation and growth. However, no population-based study to date has investigated this potential association.
objectiveThis work aims to determine whether prior angiotensin-converting enzyme inhibitor (ACEi) use is associated with a reduced odds of leiomyoma development.
designA nested case-control study was conducted.
settingThe population was assembled from the Truven Health MarketScan Research Database, which includes private health insurance claims from January 1, 2012 to December 31, 2017. PATIENTS OR OTHER
participantsWe included (n = 353 917) women age 18 to 65 with hypertension. Cases (n = 13 108) with a leiomyoma diagnosis were matched to controls (n = 340 808) with no such diagnosis at a 1:26 ratio by age and region of origin within the United States.
interventionPrior ACEi use was determined from outpatient drug claims.
main outcome measureLeiomyoma development was indicated by a first-time diagnosis code.
resultsWomen on an ACEi experienced a 31.8% reduced odds of developing clinically recognized leiomyoma compared to nonusers (odds ratio [OR] 0.68; 95% CI, 0.65-0.72). This association was significant for each age group: 30 to 39 years (OR 0.86; 95% CI, 0.74-0.99), 40 to 49 years (OR 0.71; 95% CI, 0.66-0.76), 50 to 59 years (OR 0.63; 95% CI, 0.58-0.69), and 60 to 65 years (OR 0.58; 95% CI, 0.50-0.69). Of the ACEis, lisinopril (OR 0.67; 95% CI, 0.64-0.71), quinapril (OR 0.62; 95% CI, 0.41-0.92), and ramipril (OR 0.35; 95% CI, 0.23-0.50) demonstrated a significant association with reduced leiomyoma incidence.
conclusionsACEi use was associated with a reduced odds of developing clinically recognized leiomyoma in adult hypertensive women.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.